As filed with the Securities and Exchange Commission on December 8, 201730, 2021

Registration No. 333-___________________

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM S-3


REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933


[srax_s3001.jpg]Srax_logo_highres

Social Reality,

SRAX, Inc.

(Exact name of registrant as specified in its charter)


Delaware

(State or other jurisdiction of incorporation or organization)organization)


45-2925231

(I.R.S. Employer Identification Number)Number)


456 Seaton Street2629 Townsgate Rd., Suite 215

Los Angeles, CA  90013Westlake Village, Ca 91361

Telephone: (323) 694-9800

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive officesoffices)

)Paracorp Incorporated


Paracorp Incorporated

2140 S Dupont Hwy

Camden, DE 19934

Telephone: (302) 697-4590

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

———————

with a copy to:


Raul Silvestre Esq.

Silvestre Law Group, P.C.

31200 Via Colinas.2629 Townsgate Rd., Suite 200215

Westlake Village, CA 9136291361

(818) 597-7552


From time to time after effectiveness of this registration statement

(Approximate date of commencement of proposed sale to the public)


If the only securities being registered on this Form are being offered pursuant to a dividend or interest reinvestment plans, please check the following box:o


If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:þ


If this Form is to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.o


If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:o


If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box:o






If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box:o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨(Do not check if a smaller reporting company)

Smaller reporting company þ

Emerging growth company ¨


If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨


CALCULATION OF REGISTRATION FEE


Title of Each Class of Securities to be Registered Amount to be Registered Proposed Offering Price Per Share Proposed Aggregate Offering Price (1)(2) Amount  of Registration Fee
Class A Common Stock, par value $0.001 per share(1)(2) (2) —   
Preferred Stock, par value $0.01 per share  (1) (2) (2) —   
Depository Shares  (1) (2)(2) —   
Debt Securities  (1) (2) (2) —   
Warrants  (1) (2)  (2) —   
Rights  (1) (2) (2) —   
Units  (1) (2) (2) —   
Total  (1)    $100,000,000  $9,270 


 

 

Amount

 

 

Proposed

 

 

Proposed

 

 

Amount

 

Title of Each Class of

 

to be

 

 

Offering Price

 

 

Aggregate

 

 

of

 

Securities to be Registered

 

Registered (1)

 

 

Per Share

 

 

Offering Price

 

 

Registration Fee

 

Class A Common Stock, par value $0.001 underlying 12.5% Series A-1 and A-2 Senior Secured Convertible Debentures

 

 

3,700,118

 

 

$

5.7705

(2)

 

$

21,351,531

 

 

$

2,658.27

 

Class A Common Stock underlying $3.00 Series A Warrants

 

 

863,365

 

 

$

5.7705

(2)

 

$

4,982,048

 

 

$

620.27

 

Class A Common Stock underlying $3.75 Placement Agent Warrants

 

 

129,176

 

 

$

5.7705

(2)

 

$

745,411

 

 

$

92.81

 

Class A Common Stock Underlying $4.49 Placement Agent Warrants

 

 

54,161

 

 

$

5.7705

(2)

 

$

312,537

 

 

$

38.92

 

Total

 

 

4,746,820

 

 

 

 

 

 

$

27,391,527

 

 

$

3,410.27

 


(1)

ToThere are being registered hereunder such indeterminate amount of shares of common stock and preferred stock, such indeterminate number of warrants, rights and purchase contracts to purchase common stock or preferred stock, and such indeterminate number of units as may be sold by the extent permittedRegistrant from time to time, which together shall have an aggregate initial offering price not to exceed $100,000,000 (the “Shelf Securities”). Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. The proposed maximum initial offering price per unit will be determined, from time to time, by the registrant in connection with the issuance by the registrant of the securities registered hereunder. The securities registered also include such indeterminate number of shares of common stock and preferred stock as may be issued upon conversion of or exchange for preferred stock that provide for conversion or exchange, upon exercise of warrants or rights or performance of purchase contracts or pursuant to the anti-dilution provisions of any such securities. In addition, pursuant to Rule 416 ofunder the Securities Act of 1933, as amended, this registration statement also coversthe shares being registered hereunder include such additionalindeterminate number of shares of Class A common stock ofand preferred stock as may be issuable with respect to the shares being registered hereunder as a currently indeterminable amount, in the eventresult of stock splits, stock dividends or similar transactions.

(2)

Estimated solely forThe proposed maximum aggregate offering price per class of security will be determined from time to time by the purposeregistrant in connection with the issuance by the registrant of calculating the registration feesecurities registered hereunder and is not specified as to each class of security pursuant to Rule 457General Instruction II.D. of Form S-3 under the Securities Act of 1933, as amended. Based upon the average of the high and low prices of the registrant’s Class A Common Stock on December 4, 2017.

Act.

 

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.


 






 


The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.


SUBJECT TO COMPLETION, DATED December 8, 2017DECEMBER 30, 2021


PROSPECTUS


[srax_s3002.jpg]Srax_logo_highres


Social Reality,SRAX, Inc.


$100,000,000

4,746,820 SHARES OF

CLASS A COMMON STOCK


PREFERRED STOCK

The selling stockholders namedDEPOSITORY SHARES

DEBT SECURITIES

RIGHTS

WARRANTS

UNITS

From time to time, we may offer and sell up to an aggregate amount of $100,000,000 of any combination of the securities described in this prospectus, (“Selling Stockholders”) are offering up to 4,746,820 Class A common shares consisting of: (i) up to 3,700,118 shares (assuming aeither individually or in combination, in one or more offerings. We may also offer securities as may be issuable upon conversion, floorredemption, repurchase, exchange or exercise of $1.40 per share) underlying our 12.5% senior secured convertible debentures (“Debentures”), (ii) 863,365 shares underlying Series A purchase warrants (“Warrants”) which have an initial exercise price of $3.00 per share (subject to adjustment pursuant to the terms therein) and a term of five years from issuance, (iii) 129,176 shares underlying placement agent warrants which have an initial exercise price of $3.75 per share (subject to adjustment pursuant to the terms therein) and a term of five and one half (5.5) years, and (iv) 54,161 shares underlying placement agent warrants which have an initial exercise price of $4.49 per share (subject to adjustment pursuant to the terms therein) and a term of five and one half (5.5) (collectively, all placement agent warrants are referred to as the “Placement Agent Warrants”). The Debentures, Warrants and Placement Agent Warrants were issued on October 27, 2017 pursuant to a private placement of our securities. any securities registered hereunder, including any applicable antidilution provisions.

We will not receiveprovide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any proceeds fromrelated free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the resaleapplicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the Class A common shares by the Selling Stockholders. Any proceeds received by us from the exercise of the Warrants and Placement Agent Warrants will be used for general corporate purposes.securities being offered.

 

Our Class A common stock is listed on the NASDAQ CapitalNasdaq Global Market under the trading symbol “SRAX”“SRAX.” On December 4, 2017,28, 2021, the last reported sale price of our common stock was $5.58$4.52 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Global Market or other securities exchange of the securities covered by the applicable prospectus supplement.

The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.

 

Our principal executive offices areoffice is located at 456 Seaton Street, Los Angeles,2629 Townsgate Rd., Suite 215, Westlake Village, CA 90013,91361, and our telephone number 323-694-9800.is (323) 694-9800.

 

————————————

Investing in our common stocksecurities involves a high degree of risk. You are urged to readshould review carefully the section entitledrisks and uncertainties described under the heading “Risk Factors” beginning on page 72 of this prospectus which describesand any similar section contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific risksoffering, and other informationunder similar headings in the documents that should be considered before you make an investment decision.are incorporated by reference into this prospectus.

 

————————————This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

This prospectus is dated            , 20172021













 


TABLE OF CONTENTS


Page

Page

About This Prospectus

1

Forward-Looking StatementsRisk Factors

2

Special Note Regarding Forward Looking Statements

2
Our Business

3

2

Risk Factors

4

Use of Proceeds

3
Description of Capital Stock3
Description of Class A Common Stock4
Description of Preferred Stock7
Description of Depositary Shares8
Description of Debt Securities10
Description of Rights

417

DeterminationDescription of Offering PriceWarrants

4

18

Selling StockholdersDescription of Units

5

19

Plan of Distribution

8

19

Description of Securities to be Registered

10

Legal Matters

14

21

Experts

14

21

Incorporation of DocumentsWhere You Can Find More Information

21
Information Incorporated by Reference

14

22



i

 






 


ABOUT THIS PROSPECTUS


Unless the context requires otherwise or unless otherwise noted, all references in this prospectus to“our company,” “we,” “our,” “Social Reality” and “us” refer to Social Reality, Inc. and its subsidiary. Also, any reference to “common share” or “common stock,” refers to our $0.001 par value Class A common stock. All share and per share information contained in this prospectus takes into account the 1-for-5 reverse stock split of our Class A common shares effective September 22, 2016.

 

This prospectus is part of a registration statement on Form S-3 that we have filed with the U.S. Securities and Exchange Commission, (the “SEC”) underor the Securities Act of 1933, as amended (the “Securities Act”).SEC, using a “shelf” registration process. Under this shelf registration process, holders of the Debentures, Warrants, and Placement Agent Warrantswe may, from time to time, offer and sell, either individually or otherwise dispose ofin combination, in one or more offerings, up to an aggregatea total dollar amount of 4,746,820 Class A common shares issued to them upon their respective conversion or exercise. The registration statement containing$100,000,000 of any combination of the securities described in this prospectus.

This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, including the exhibits to the registration statement, provides additionalwe will provide a prospectus supplement that will contain more specific information about usthe terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the securities offered underinformation contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. The registration statement, includingWe urge you to read carefully this prospectus, any applicable prospectus supplement and any free writing prospectuses we have authorized for use in connection with a specific offering, together with the exhibits, can be read on the SEC’s website or at the SEC offices mentionedinformation incorporated herein by reference as described under the heading “Where You Can Find More Information.“Information Incorporated by Reference, before buying any of the securities being offered.

This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.

 

You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. We have not authorizedprospectus, the accompanying prospectus supplement or in any other personrelated free writing prospectus that we may authorize to provide you with different information. If anyone provides you with different information, you should not rely on it. We are not makingbe provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.

The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.

This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these securities insources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any jurisdiction wheremisstatements regarding the offer or sale is not permitted. You should assume that the information containedmarket and industry data presented in this prospectus and the documents incorporated herein by reference, hereinthese estimates involve risks and thereinuncertainties and are accurate only as ofsubject to change based on various factors, including those discussed under the date such information is presented orheading “Risk Factors” contained in anythe applicable prospectus supplement. Neithersupplement and any related free writing prospectus, and under similar headings in the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implicationother documents that there has been no change in our affairs since the date of this prospectus or that the information containedare incorporated by reference tointo this prospectus is correct as of any time after its date.prospectus. Accordingly, investors should not place undue reliance on this information.

 

This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may be supplemented from time to time to add, update or change information in this prospectus. Any statement containedobtain copies of those documents as described below under the section entitled “Where You Can Find More Information.”

As used in this prospectus, will be deemedunless context otherwise requires, the words “we,” “us,” “our,” “the Company,” “SRAX,” “Registrant” refer to be modified or superseded for purposes of this prospectusSRAX, Inc. and its subsidiaries. Additionally, any reference to (i) “LD Micro” refers to the extent that a statement containedCompany’s wholly owned subsidiary, “LD Micro, Inc.” and the assets used in such prospectus supplement modifiesits operation. Also, any reference to “common share” or supersedes such statement. Any statement so modified will be deemed“common stock,” refers to constitute aour $.001 par value Class A common stock.

Unless otherwise stated, the information which appears on our web site www.srax.com is not part of this prospectus only as so modified,report and any statement so superseded will be deemedis specifically not to constitute a part of this prospectus.incorporated by reference.


1

RISK FACTORS

 





FORWARD-LOOKING STATEMENTS

The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act", and Section 21E of the Securities Exchange Act of 1934, as amended, or the "Exchange Act".

Such statementsInvesting in connection with any discussion of future operations or financial performance are identified by the use of words such as “may,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning. Forward-looking statements include, but are not limited to, statements about: our business, operations, financial performance and condition, earnings, our prospects, our ability to raise capital to fund our operations and business plan, the continued listing of our securities oninvolves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the NASDAQ Capital Market, our ability to protect intellectual property rights as well as regarding our industry generally. Forward–looking statements are not guarantees of performance. Such statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timingdescribed under the heading “Risk Factors” contained in the applicable prospectus supplement, and performance to differ materially from those expressed or implied by such statements. For a summary of such factors, please refer todescribed under the section entitledtitled “Risk Factors” in this prospectus, as updated and supplemented by the discussion of risks and uncertaintiescontained in our most recent annual report on Form 10-K as revised or supplemented byand in our subsequentmost recent quarterly reportsreport on Form 10-Q, or our current reports on Form 8-K, as well as any amendments thereto, as filedsubsequent filings with the SEC, and which are incorporated hereinby reference into this prospectus, together with other information in this prospectus and the documents incorporated by reference. The information containedrisks described in this document is believed to be current as ofthese documents are not the date of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

In light of these assumptions,only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be materially adversely affected. This could cause the results and events discussedtrading price of our securities to decline, resulting in a loss of all or part of your investment. Please also carefully read the forward-lookingsection titled “Special Note Regarding Forward-Looking Statements.”

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this prospectus, or in any document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance onincluding the forward-looking statements, which speak only as of the date of this prospectus or the date of the documentdocuments incorporated by reference in this prospectus. Weprospectus, may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not underlimited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any obligation,statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:

our ability to continue as a going concern;
our reliance on third party vendors;
our dependence on our executive officers;
our financial performance guidance;
material weaknesses in our internal control over financial reporting;
regulatory developments in the United States and foreign countries;
the impact of laws, regulations, accounting standards, regulatory requirements, judicial decisions and guidance issued by authoritative bodies;
our estimates regarding expenses, future revenue and cash flow, capital requirements and needs for additional financing;
our financial performance;
the ability to recognize the anticipated benefits of our business combination and/or divestitures; and
the effect of COVID-19 on the foregoing.

The forward-looking statements contained or incorporated by reference in this prospectus are based on current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we expressly disclaimhave anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section titled “Risk Factors” and elsewhere in this prospectus, our most recent Annual Report on Form 10-K and our most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update or alterrevise any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.


otherwise, except as may be required under applicable securities laws.


2






OUR BUSINESS


We are an Internet advertisinga technology firm focused on enhancing communications between public companies and platform technology company that provides tools to automate the digital advertising market. Our focus is to provide technology tools that enable both publishers and advertisers to maximize their digital advertising initiatives. We derive our revenues from:


·

sales of digital media advertising campaigns to advertising agencies and brands;

·

sales of media inventory through real-time bidding, or "RTB," exchanges;

·

sale and licensing of our SRAX Social platform and related media; and

·

creation of custom platforms for buying media on SRAX for large brands.


The core elements of our business are:


·

Social Reality Ad Exchange or "SRAX" – Real Time Bidding sell side and buy side representation is our technology which assists publishers in delivering their media inventory to the RTB exchanges. The SRAX platform integrates multiple market-leading demand sources, including OpenX, Pubmatic and AppNexus. We also build custom platforms that allow our agency partners to launch and manage their own RTB campaigns by enabling them to directly place advertising orders on the platform dashboard and view and analyze results as they occur;

·

SRAXmd is our ad targeting and data platform for healthcare brands, agencies and medical content publishers. Healthcare and pharmaceutical publishers utilize the platform for yield optimization, audience extension campaigns and re-targeting of their healthcare professional audience. Agencies and brands purchase targeted digital and mobile ad campaigns;

·

SRAX Social is a social media and loyalty platform that allows brands to launch and manage their social media initiatives. Our team works with customers to identify their needs and then helps them in the creation, deployment and management of their social media presence; and

·

SRAX app, a recently launched new product, which is a platform that allows publishers and content owners to launch native mobile applications through our SRAX platform. The SRAX app is a free platform that provides online publishers an opportunity to distribute their content via a branded mobile application that updates automatically as they publish new content to their website. The platform also allows publishers the opportunity to bring in influencer feeds from Facebook, Instagram, YouTube and Twitter that are relevant to their content.


We offer our customers several pricing options including cost-per-thousand-impression, commonly referred to as CPM, whereby our customers pay based on the number of times the target audience is exposed to the advertisement, and on a monthly service fee.


Corporate information


We were incorporated in Delaware in 2011. Our principal executive offices are located at 456 Seaton Street, Los Angeles, CA 90013, and our telephone number is (323) 694-9800. Our website is located atwww.srax.com.


investors. We have not incorporated by reference into this prospectus,two distinct operating segments. Our unique SaaS platform assists issuers in tracking their shareholders’ behaviors and trends, then using data-driven insights to engage with investors across marketing channels. Through our LD Micro operating segment, we organize and host investor conferences within the information in, or that can be accessed through, our websitemicro and you should not consider it to be a part of this prospectus.



small- cap markets.

 





RISK FACTORS


An investment in our Class A common stock involves a significant degree of risk. You should not invest in our Class A common stock unless you can afford to lose your entire investment. You should consider carefully the risk factors and other information contained in in our most recent Annual Report on Form 10-K, as revised or supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our most recent Annual Report on Form 10-K, each of which are on file with the SEC and are incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus.



USE OF PROCEEDS


This prospectus relates to shares of our Class A common stock that may be offered and sold from time to time by the Selling Stockholders. There will be no proceeds to us from the sale of shares of Class A common stock in this offering. In the event the Warrants and Placement Agent Warrants held by the Selling Stockholders are exercised for cash, we will receive approximately $3,317,688, assuming the initial exercise prices are not adjusted pursuant to the terms thereunder. We will use the proceeds received from the exercise of the Warrants and Placement Agent Warrants, if any, for general corporate purposes.


DETERMINATION OF OFFERING PRICE

This offering is being made solely to allow the Selling Stockholders to offer and sell the securities to the public. The Selling Stockholders may offer for resale some or all of their securities at the time and price that they choose pursuant to the Plan of Distribution. On any given day, the price of our common shares will be based on the market price for our Class A common shares, as quoted on the NASDAQ Capital Market under the symbol “SRAX”.







SELLING STOCKHOLDERS

This prospectus relates to the offering and sale, from time to time, by the Selling Stockholders of up to 4,746,820 Class A common shares which are issuable upon (i) the conversion of $5,180,157.78 in principal of Debentures into a maximum of 3,700,118 shares (assuming a conversion floor of $1.40 per share), (ii) the exercise of 863,365 Warrants which have an initial exercise price of $3.00 per share (subject to adjustment pursuant to the terms therein), (iii) the exercise of 129,176 Placement Agent Warrants which have an initial exercise price of $3.75 per share (subject to adjustment pursuant to the terms therein, and (iv) the exercise of 54,161 Placement Agent Warrants which have an initial exercise price of $4.49 per share (subject to adjustment pursuant to the terms therein). The securities were issued in a private placement on October 27, 2017.Sequire

 

The Selling Stockholders may convert or exerciseSequire platform allows companies to engage with their respective Debenturesshareholders, manage their outstanding securities, and Warrants at any time in their sole discretion.identify potential investors. The Selling Stockholders may exercise their Placement Agent Warrants, as applicable, six (6) months from the date of their issuance.


Set forth below isplatform utilizes machine learning and advanced analytics to bring our clients actionable information to the extent known to us, setting forth the name of each Selling Stockholder and the amount and percentage of Class A common stock owned by each (including Class A common shares that can be acquired on the conversion of outstanding debentures or the exercise of outstanding warrants) priorused to the offering, the Class A common shares to be sold in the offering, and the amount and percentage of common stock to be owned by each (including shares that can be acquired on the conversion of outstanding debentures and the exercise of outstanding warrants) after the offering assuming all shares are sold. The footnotes provide information about persons who have voting and dispositive power for the Selling Stockholders and about transactions between the Selling Stockholders and the Company, if any.maximize ROI, as an innovative investor communication tool.

 

The Selling Stockholders may sell all or someSequire platform assists our customers in understand shareholder behavior, including the ability to identify buyers and sellers of the customer’s securities. Clients then have the ability to engage with targeted shareholder groups across marketing channels including email, social media, programmatic, and hyperlocal. When interpreting data, clients can see gains and losses over time, buying/selling trends, total outstanding shares, new shareholders, and shareholders broken out by percentage. Every bit of Class A common stockthis data helps how we target ads and craft messaging to leverage the desired outcome for a client.

The Sequire platform also provides users tools related to the management of their back-office and analytics. For example, the platform provides tools to that manage outstanding option and warrant assisting users with their SEC reporting and disclosure obligations. Additionally, the platform now includes the ability to host virtual events, as more and more networking functions are being held in the digital space. Clients can attend an event held by industry guests or hold a conference themselves.

Data Targeting

Using data-driven insights, we help clients meet their unique marketing objectives, whether they’re messaging existing investors, new investors, or consumers. Through the use of this data, clients are able to expand their investor base through targeted advertising and marketing campaigns, tailored to their needs. By assisting clients to develop a unique messaging to suit their target investors. Once media campaigns are built, they are offering, and may sell shares of our Class A common stock otherwise than pursuant to this prospectus. The table below assumes that each selling stockholder converts all of its Debentures, exercises all of its Warrants and Placement Agent Warrants, and sells all ofrun through the Class A common shares issued upon exercise thereof, and that each Selling Stockholder sells all of the Class A common shares offered by it in offerings pursuant to this prospectus, and does not acquire any additional Class A common shares. We are unable to determine the exact number of Class A shares that will actually be sold or when or if these sales will occur.


Unless otherwise stated below in the footnotes, to our knowledge, no Selling Stockholder nor any affiliate of such stockholder: (i) has held any position or office with, been employed by or otherwise has had any material relationship with us or our affiliates during the three years prior to the date of this prospectus; or (ii) is a broker-dealer, or an affiliate of a broker-dealer.Sequire platform across multiple target segments.

 

We may amend or supplement this prospectus from timeare maximizing the efficacy of our media campaigns by providing our clients with custom-built landing pages that are crafted to time in the futureeducate, engage, and convert new investors. When a new investor clicks through an ad, they will land on a story-driven page with data-tracking software embedded to update or change this listcollect analytics for later use.

Virtual Events and Class A common shares which may be resold.LD Micro






The table below lists the selling shareholdersIn September of 2020, we acquired LD Micro and other information regarding the beneficial ownershipbegan development of the sharesSequire Virtual Events platform. The platform allows users to host a variety of Class A common stock by each ofvirtual events and conferences including: investor conferences, earnings calls, shareholder meetings, annual, investor/analyst days, corporate town halls, roadshows, and more. In 2020 we hosted the Selling Stockholders.LD Micro Main Event on our Sequire Virtual Events platform. The totalevent attracted more than 50 thousand attendees and 250 companies presented. Since acquiring LD Micro, we have expanded the number of Class A common shares sold under thisinvestor conferences to include specialty conferences for individual industries such as: EdTech, FinTech, Minerals, Pharma, etc.

USE OF PROCEEDS

Except as described in any applicable prospectus may be adjustedsupplement, we intend to reflect adjustments due to stock dividends, stock distributions, splits, combinations, recapitalizations oruse the triggering anti-dilution protective provisions with regard to the Class A common stock underlying the Debentures, Warrants, and Placement Agent Warrants, as applicable.


 

 

Class A Common Shares
Owned Before Sale (1)

 

 

 

 

 

Class A Common Shares
Owned After Sale (2)

 

 

 

Held
Outright

 

 

Convertible
Securities

 

 

Amount

 

 

% of class

 

 

Shares being
registered

 

 

Amount

 

 

% of Class

 

ATW Master Fund II, L.P. (3)

 

 

 

 

 

4,168,905

 

 

 

4,168,905

 

 

 

30.89

%

 

 

2,801,571

 

 

 

1,367,334

 

 

 

10.13

%

Anson Investments Master Fund LP (4)

 

 

 

 

 

880,953

 

 

 

880,953

 

 

 

8.63

%

 

 

880,953

 

 

 

 

 

 

*

 

Puritan Partners LLC (5)

 

 

 

 

 

550,477

 

 

 

550,477

 

 

 

5.57

%

 

 

440,477

 

 

 

110,000

 

 

 

1.11

%

Christopher Scott Wrolstad (6)

 

 

350,000

 

 

 

96,497

 

 

 

446,497

 

 

 

4.74

%

 

 

96,497

 

 

 

350,000

 

 

 

3.71

%

Steve Ossello (7)

 

 

120,166

 

 

 

52,450

 

 

 

172,616

 

 

 

1.84

%

 

 

52,450

 

 

 

120,166

 

 

 

1.28

%

3983 LLC (8)

 

 

120,166

 

 

 

44,049

 

 

 

164,215

 

 

 

1.75

%

 

 

44,049

 

 

 

120,166

 

 

 

1.28

%

Richard Schmitz (9)

 

 

 

 

 

88,096

 

 

 

88,096

 

 

 

0.94

%

 

 

88,096

 

 

 

 

 

 

*

 

Jeffrey J. Schmitz (10)

 

 

 

 

 

88,096

 

 

 

88,096

 

 

 

0.94

%

 

 

88,096

 

 

 

 

 

 

*

 

H. Leigh Severance (11)

 

 

160,758

 

 

 

88,096

 

 

 

248,854

 

 

 

2.64

%

 

 

88,096

 

 

 

160,758

 

 

 

1.71

%

Chardan Capital Markets, LLC (12)

 

 

 

 

 

94,156

 

 

 

94,156

 

 

 

1.00

%

 

 

30,290

 

 

 

63,866

 

 

 

*

 

Jonathan Schechter (13)

 

 

41,250

 

 

 

165,420

 

 

 

206,670

 

 

 

2.18

%

 

 

54,710

 

 

 

151,960

 

 

 

1.60

%

Joseph Reda (14)

 

 

232,500

 

 

 

150,000

 

 

 

382,500

 

 

 

4.04

%

 

 

75,000

 

 

 

307,500

 

 

 

3.25

%

Colorado Financial Sevrice Corporation (15)

 

 

 

 

 

2,334

 

 

 

2,334

 

 

 

0.03

%

 

 

2,334

 

 

 

 

 

 

*

 

Harold Reed Madison (16)

 

 

 

 

 

4,201

 

 

 

4,201

 

 

 

0.05

%

 

 

4,201

 

 

 

 

 

 

*

 

 

 

 

1,024,840

 

 

 

6,473,730

 

 

 

7,498,570

 

 

 

47.46

%

 

 

4,746,820

 

 

 

2,751,750

 

 

 

17.42

%

———————

*

Represents less than 1%


**

Unless otherwise stated, the individual(s) with voting and dispositive control of securities offered on behalf of trusts or custodial accounts is the individual or entity referenced in the name of such accounts.


(1)

Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any Class A common shares (“Common Shares”) as to which a shareholder has sole or shared voting power or investment power, and also any Common Shares which the shareholder has the right to acquire within 60 days, including upon exercise of Common Shares purchase options or warrants or upon conversion of debentures. There were 9,325,430 Common Shares outstanding as of December 4, 2017. All shares referenced below are Common Shares.


(2)

Includes the sale of all Common Shares registered herein.


(3)

The shares being registered include (i) 2,271,543 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 530,028 shares underlying warrants pursuant to our October 2017 Offering. Kerry Propper has voting and dispositive control with respect to the securities being offered. Kerry Propper is also a principal at Chardan Capital Markets, LLC, a registered broker-dealer.







(4)

The shares being registered include (i) 714,286 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 166,667 shares underlying warrants pursuant to our October 2017 Offering. Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson Investments Master Fund LP (“Anson”), hold voting and dispositive power over the Common Shares held by Anson. Bruce Winson is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Adam Spears are directors of Anson Advisors Inc. Mr. Winson, Mr. Kassam and Mr. Spears each disclaim beneficial ownership of these Common Shares except to the extent of their pecuniary interest therein. The principal business address of Anson is 190 Elgin Ave; George Town, Grand Cayman.


(5)

The shares being registered include (i) 357,143 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 83,334 shares underlying warrants pursuant to our October 2017 Offering. Richard Smithline has voting and dispositive control with respect to the securities being offered.


(6)

The shares being registered include (i) 71,429 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering, (ii) 16,667 shares underlying warrants pursuant to our October 2017 Offering, and (iii) 8,401 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Christopher Scott Wrolstad is an affiliated person of Colorado Financial Service Corporation and Aspenwood Capital, registered broker-dealers.


(7)

The shares being registered include (i) 35,715 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering, (ii) 8,334 shares underlying warrants pursuant to our October 2017 Offering, and (iii) 8,401 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Steve Ossello is an affiliated person of Colorado Financial Service Corporation and Aspenwood Capital, registered broker-dealers.


(8)

The shares being registered include (i) 35,715 shares underlying convertible debentures (based on a good faith estimated conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 8,334 shares underlying warrants pursuant to our October 2017 Offering. Steve Ossello has voting and dispositive control with respect to the securities being offered. Steve Ossello is an affiliated person of Colorado Financial Service Corporation and Aspenwood Capital, registered broker-dealers.


(9)

The shares being registered include (i) 71,429 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 16,667 shares underlying warrants pursuant to our October 2017 Offering.


(10)

The shares being registered include (i) 71,429 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 16,667 shares underlying warrants pursuant to our October 2017 Offering.


(11)

The shares being registered include (i) 71,429 shares underlying convertible debentures (based on a conversion floor price of $1.40) pursuant to our October 2017 Offering and (ii) 16,667 shares underlying warrants pursuant to our October 2017 Offering.


(12)

The shares being registered include 30,290 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Chardan Capital Markets, LLC is a registered broker-dealer. Steven Urbach has voting and dispositive control with respect to the securities being offered. Kerry Propper, a principal at Chardan Capital Markets, LLC is controlling person of ATW Master Fund II and its associated entities, which are senior secured lenders of the Company.


(13)

The shares being registered include 54,710 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Jonathan Schechter is an affiliated person of Chardan Capital Markets, LLC, a registered broker-dealer.


(14)

The shares being registered include 75,000 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Joseph Reda is an affiliated person of Chardan Capital Markets, LLC, a registered broker-dealer.


(15)

The shares being registered include 2,334 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Colorado Financial Service Corporation is a registered broker-dealer. Chester J Hebert has voting and dispositive control with respect to the securities being offered.


(16)

The shares being registered include 4,201 shares underlying warrants issued for placement agent services pursuant to our October 2017 Offering. Harold Reed Madison is an affiliated person of Colorado Financial Service Corporation and Aspenwood Capital, registered broker-dealers.





PLAN OF DISTRIBUTION


Each Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may,net proceeds from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:


·

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

·

block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

·

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

·

an exchange distribution in accordance with the rules of the applicable exchange;

·

privately negotiated transactions;

·

settlement of short sales;

·

in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;

·

through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

·

a combination of any such methods of sale; or

·

any other method permitted pursuant to applicable law.


The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.


Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.


In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered byunder this prospectus which securities such broker-dealer orfor working capital and other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).


The Selling Stockholders and any broker-dealers or agents that are involved in sellinggeneral corporate purposes. We have not determined the securities may be deemedamount of net proceeds to be “underwriters” withinused specifically for such purposes. As a result, our management will retain broad discretion over the meaningallocation of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.


net proceeds. We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.






We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for our company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for saleset forth in the applicable state or an exemptionprospectus supplement our intended use for the net proceeds received from the registration or qualification requirement is available and is complied with.


Under applicable rules and regulations undersale of any securities. Pending the Exchange Act, any person engaged in the distributionuse of the resale securitiesnet proceeds, we may not simultaneously engagetemporarily invest the net proceeds in market making activities with respect to the Class A common stock for the applicable restricted period, as defined in Regulation M, prior to the commencementa variety of capital preservation instruments, including investment grade instruments, certificates of deposit or direct or guaranteed obligations of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, whichU.S. government, or may limit the timing of purchases and sales of the Class A common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).hold such proceeds as cash, until they are used for their stated purpose.







DESCRIPTION OF SECURITIES TO BE REGISTEREDCAPITAL STOCK


General

 

The following is a summary of the rights of our common stock and preferred stock and relatedcertain provisions of our certificate of incorporationsecurities does not purport to be complete and bylaws. For more detailed information, please seeis subject to our certificate of incorporation and bylaws whichand the provisions of applicable law. Copies of our amended and restated certificate of incorporation and bylaws are filed as exhibits to the registration statement of which this prospectus is a part.

 

3

Our certificate of incorporation provides that we will have two classes of common stock:

Class A common stock, which has one vote perCommon Stock

Authorized Capitalization

General

The total amount of our authorized share and Class B common stock, which has ten votes per share. Any holdercapital consists of Class B common stock may convert his or her shares at any time into250,000,000 shares of Class A common stock, on a share-for-share basis. Otherwise the rights of the two classes of common stock will be identical. The rights of these classes of common stock are discussed in greater detail below.

Our authorized capital stock consists of 309,000,000 shares, each with a par value of $0.001 per share, of which:


·

250,000,000 shares are designated as Class A common stock;


·

9,000,000 shares are designated as Class B common stock; and


·

50,000,000 shares are designated asof preferred stock.

As of September 30, 2017,stock, par value $0.001 per share. Previously we had 8,232,830 shares of Class A common stock outstanding and noauthorized 9,000,000 shares of Class B common stock, par value $0.001, of which all have been retired and cannot be reissued.

Common Stock Rights

Voting rights. Each holder of common stock is entitled to one vote for each share of common stock held of record by such holder on all matters voted upon by our stockholders, provided, however, that, except as otherwise required in our certificate of incorporation or by applicable law, the holders of common stock are not entitled to vote on any amendment to our certificate of incorporation that relates solely to the terms of one or more outstanding series of preferred stock outstanding.if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to our certificate of incorporation (including any certificate of designation relating to any series of preferred stock) or pursuant to the General Corporation Law of the State of Delaware, or the DGCL.

 

Common Stock

Voting RightsDividend rights

Holders. Subject to the rights of holders of preferred stock and any other provisions of our Class A and Class B common stock have identical rights, except thatcertificate of incorporation, as it may be amended from time to time, holders of our Class Ashares of common stock are entitled to one vote per share and holders of our Class B common stock are entitledreceive ratably, in proportion to ten votes per share. Holdersthe number of shares of Class Acommon stock held by them, such dividends and other distributions in cash, stock or property when, as and if declared thereon by our board of directors from time to time out of our assets or funds legally available therefor.

Rights upon liquidation. Subject to the rights of holders of preferred stock, in the event of any liquidation, dissolution or winding up of our affairs, whether voluntary or involuntary, after payment or provision for payment of our debts and any other payments required by law and amounts payable upon shares of preferred stock ranking senior to the shares of common stock upon such dissolution, liquidation or winding up, if any, our remaining net assets will be distributed to the holders of shares of common stock and Class Bthe holders of shares of any other class or series ranking equally with the shares of common stock will vote together asupon such dissolution, liquidation or winding up, equally on a single class on all matters (including the electionper share basis.

Other rights. No holder of directors) submitted to a voteshares of stockholders, unless otherwise required by law. Delaware law could require either our Class A common stock is entitled to preemptive or Class B common stock to vote separately as a single class in the following circumstances:

·

If we amended our certificate of incorporation to increase the authorized shares of a class of stock, or to increase or decrease the par value of a class of stock, then that class would be required to vote separately to approve the proposed amendment.

·

If we amended our certificate of incorporation in a manner that altered or changed the powers, preferences or special rights of a class of stock in a manner that affects them adversely then that class would be required to vote separately to approve the proposed amendment.

We have not provided for cumulative voting for the election of directorssubscription rights contained in our certificate of incorporation.

Dividends

Subjectincorporation or bylaws. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences that may applyand privileges of holders of the common stock will be subject to those of the holders of any shares of preferred stock outstanding at the time, the holders of Class A common stock and Class B common stock shall be entitled to share equally in any dividendswith preferential rights that our board of directorswe may determine to issue from time to time. In the event a dividend is paid in the form of shares of common stock or rights to acquire shares of common stock, the holders of Class A common stock shall receive Class A common stock, or rights to acquire Class A common stock, as the case may be, and the holders of Class B common stock shall receive Class B common stock, or rights to acquire Class B common stock, as the case may be.future.

 

Liquidation Rights

Upon our liquidation, dissolution or winding-up, the holdersAnti-takeover effects of Class A common stock and Class B common stock shall be entitled to share equally all assets remaining after the payment of any liabilities and the liquidation preferences on any outstanding preferred stock.





Subdivision or Combinations.

Upon the subdivision or combination of the outstanding shares of one class of Common Stock, the outstanding shares of the other class of Common Stock will be subdivided or combined in the same manner.

Conversion

Our Class A common stock is not convertible into any other shares of our capital stock.

Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock shall convert automatically into one share of Class A common stock upon any transfer, whether or not for value, except for certain transfers described in our certificate of incorporation, including the following:

·

Transfers between one Class B Stockholder to another Class B Stockholder.

·

Transfers for tax and estate planning purposes, including to trusts, corporations and partnerships controlled by a holder of Class B common stock.

The death of any holder of Class B common stock who is a natural person will result in the conversion of his or her shares of Class B common stock to Class A common stock. Once transferred and converted into Class A common stock, the Class B common stock shall not be reissued. No class of common stock may be subdivided or combined unless the other class of common stock concurrently is subdivided or combined in the same proportion and in the same manner.


Dual Class Structure

As discussed above, our Class B common stock has ten votes per share, while our Class A common stock, which is the class of stock the Selling Stockholders are selling pursuant to this prospectus and which is the only class of stock which is publicly traded, has one vote per share. We currently have no shares of our Class B common stock outstanding. Notwithstanding, in the event Class B common stock were issued, due to our dual class structure with superior voting rights, such ownership of Class B common stock could discourage others from initiating any potential merger, takeover or other change of control transaction that other stockholders may view as beneficial.

Preferred Stock

Our board of directors will have the authority, without approval by the stockholders, to issue up to a total of 50,000,000 shares of preferred stock in one or more series. Our board of directors may establish the number of shares to be included in each such series and may fix the designations, preferences, powers and other rights of the shares of a series of preferred stock. Our board could authorize the issuance of preferred stock with voting or conversion rights that could dilute the voting power or rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of Social Reality. We have no current plans to issue any shares of preferred stock.


Debentures


On October 26, 2017, we offered and sold the Debentures, and (ii) five year Series A common stock purchase warrants (the “Series A Warrants”) (the “Offering”). Pursuant to the terms of the Debentures, and assuming a reduction in the price floor (as described below) and an adjustment in conversion price, holders of the Debentures may receive up to 3,700,118 shares of our Class A Common stock.


The Debentures, which mature on April 21, 2020,pay interest in cash at the rate of 12.5% per annum, payable quarterly on January 1, April 1, July 1 and October 1, beginning on January 1, 2018. Our obligations under the Debentures are secured by substantially all our assets. The Debentures are convertible at the option of the holder into shares of our Class A common stock at an initial conversion price of $3.00 per share, subject to adjustment.






The Debentures were issued in two series, Series A-1 Debentures (“A-1 Debentures”) and Series A-2 Debentures (“A-2 Debentures”). The A-1 Debentures and A-2 Debentures are substantially the same except that the A-1 Debentures have a conversion price floor of $1.40 with regard to anti-dilution protection for subsequent equity sales at a price lower than 120% of the then applicable conversion price. The A-2 Debentures have a conversion price floor of $3.00 until such time as the Company receives shareholder approval for the transaction at which time the price floor will be adjusted to $1.40.

Subject to our compliance with certain equity conditions (as more fully set forth in the Debentures), upon 20 trading days' notice to the holders we have the right to redeem the Debentures in cash at a 120% premium during the first year and a 110% premium during the remaining term of the Debentures. Upon any optional redemption, we are obligated to issue the holder Series B warrants, the terms of which will be identical to the Series A Warrants, to purchase a number of shares of our Common Stock equal to 50% of the conversion shares issuable on an as-converted basis as if the principal amount of the Debenture had been converted immediately prior to the optional redemption. In the event of future financings by us, subject to certain exempt issuances, the holders have the right to cause us to allocate 20% of the proceeds we receive to redeem a portion of the principal amount of the then outstanding Debentures. We are also required to redeem the Debentures, at the holder’s right, upon our failure to maintain certain financial covenants as further described in the Debentures.


The Debentures also contain certain customary events of default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, changes in control of the Company and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such event of default, the outstanding principal amount of the Debenture for a premium, plus liquidated damages, interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the holder’s election, immediately due and payable in cash. The Company is also subject to certain negative covenants under the Debenture, including but not limited to, the creation of certain debt obligations, liens on Company assets, amending its charter documents, repayment or repurchase of securities or certain debt of the Company, or the payment of dividends.


Warrants


In connection with the Offering, we issued (i) 863,365 Series A Warrants warrants which have an initial exercise price of $3.00 per share (subject to adjustment pursuant to the terms therein) and a term of five years from issuance, (i) 129,176 placement agent warrants which have an initial exercise price of $3.75 per share (subject to adjustment pursuant to the terms therein) and a term of five and one half (5.5) years, and (iv) 54,161 placement agent warrants which have an initial exercise price of $4.49 per share (subject to adjustment pursuant to the terms therein) and a term of five and one half (5.5).

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws

Certain provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could have the effectand Delaware law

Certificate of delaying, deferring or discouraging another party from acquiring control of us. In particular, our dual class common stock structure will concentrate ownershipIncorporation and Bylaws

Provisions of our voting stockamended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the handsprice of our founders, board members,common stock. Among other things, our amended and employees. These provisions, which are summarized below, are expected to discourage coercive takeover practicesrestated certificate of incorporation and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.

Special Approval for Change in Control Transactions

In the event a person seeks to acquire us by means of a merger or consolidation transaction, a purchase of all or substantially all of our assets, or an issuance of stock which constitutes 2% or more of our outstanding shares at the time of issuanceamended and which results in any person or group owning more than 50% of our outstanding voting power, then these types of acquisition transactions must be approved by our stockholders at an annual or special meeting. At this meeting, we must obtain the approval of stockholders representing the greater of:restated bylaws:

 

permit our board of directors to issue up to 50,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;

·

A

provide that the authorized number of directors may be changed only by resolution adopted by a majority of the voting powerboard of our outstanding capital stock; and

directors;

·

60%provide that all vacancies, including newly created directorships, may, except as otherwise required by law or subject to the rights of holders of preferred stock as designated from time to time, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice and provide certain disclosure with regard to hedged positions;
do not provide for cumulative voting powerrights (therefore allowing the holders of a majority of the shares of capitalcommon stock present in person or represented by proxy at the stockholder meeting and entitled to vote.

vote in any election of directors to elect all of the directors standing for election, if they should so choose);

 

4





Undesignated Preferred Stock

 

The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.

provide that special meetings of our stockholders may be called only by the Chairman of the Board, our Chief Executive Officer, by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exists any vacancies) or by holders of more than twenty percent (20%) of the total voting power of outstanding capital stock;
provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against the us arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws, or (iv) any action asserting a claim against us governed by the internal affairs doctrine; and
provide the ability to our board of directors to authorize and designated undesignated preferred stock and issue such preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.

Requirements for Advance Notification of Stockholder Nominations and Proposals

Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. The bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.

 

Delaware Anti-Takeover StatuteLaw

We will beare subject to the provisions of Section 203 of the Delaware General Corporation Law, regulating corporate takeovers. In general,or Section 203. Section 203 generally prohibits a publicly-heldpublic Delaware corporation from engaging under certain circumstances, in a business combination“business combination” with an interested stockholder“interested stockholder” for a period of three years followingafter the date of the transaction in which the person became an interested stockholder, unless:

 

·

Priorprior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder.

stockholder;

·

Upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding atupon consummation of the time the transaction, commenced, excluding for purposes of determining the number of shares outstanding (1)(a) shares owned by persons who are directors and also officers and (2)(b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer.

offer; or

·

Onon or subsequent to the dateconsummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

 

Generally,Section 203 defines a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Aninclude:

any merger or consolidation involving the corporation and the interested stockholder;
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder is aas any entity or person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did ownbeneficially owning 15% or more of a corporation’sthe outstanding voting securities.stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

5

Limitations on Liability and Indemnification of Officers and Directors

Our certificate of incorporation limits the liability of our directors to the fullest extent permitted by the DGCL, and our bylaws provide that we will indemnify them to the fullest extent permitted by such law. We have entered and expect the existence of this provision to have an anti-takeover effect with respectcontinue to transactionsenter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. Under the terms of such indemnification agreements, we are required to indemnify each of our directors doesand officers, to the fullest extent permitted by the laws of the state of Delaware, if the basis of the indemnitee’s involvement was by reason of the fact that the indemnitee is or was a director or officer of us or any of its subsidiaries or was serving at our request in an official capacity for another entity. We must indemnify our officers and directors against all reasonable fees, expenses, charges and other costs of any type or nature whatsoever, including any and all expenses and obligations paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or preparing to defend, be a witness or participate in any completed, actual, pending or threatened action, suit, claim or proceeding, whether civil, criminal, administrative or investigative, or establishing or enforcing a right to indemnification under the indemnification agreement. The indemnification agreements also require us, if so requested, to advance within 10 days of such request all reasonable fees, expenses, charges and other costs that such director or officer incurred, provided that such person will return any such advance if it is ultimately determined that such person is not approve in advance. We also anticipate that Section 203entitled to indemnification by us. Any claims for indemnification by our directors and officers may also discourage attempts that might result in a premium overreduce our available funds to satisfy successful third-party claims against us and may reduce the market price for the sharesamount of common stock held by stockholders.money available to us.

 

The provisionsExclusive Jurisdiction of DelawareCertain Actions

Our bylaws require, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty, actions asserting a claim arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws, actions to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws and our bylaws couldactions asserting a claim against us governed by the internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel; provided, however, that the foregoing provisions will not apply to any claims arising under the Exchange Act or the Securities Act. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging others from attempting hostile takeoverslawsuits against our directors and as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.officers.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our Classcommon stock and outstanding Series A common stockPreferred Stock is Transfer Online, Inc. The transfer agent and registrar’s address is 512 SE Salmon Street, Portland, OR 97214, 503-227-2950.phone number (503) 227-2950. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement related to that series.




Listing on the Nasdaq Global Market

Our common stock is listed on the Nasdaq Global Market under the symbol “SRAX”. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq Global Market or any securities market or other exchange of the preferred stock covered by such prospectus supplement.


6


Preferred Stock

General Description

Under the terms of our amended and restated certificate of incorporation, our board of directors have the authority, without further action by our stockholders, to issue up to 50,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

Our board of directors may authorize the issuance of preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue Preferred Stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of Preferred Stock on the rights of holders of Common Stock until the board of directors determines the specific rights attached to that Preferred Stock.

Series A Preferred Stock

Pursuant to our Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Preferred Stock, or the Certificate of Designation, we designated 36,412,417 shares of our authorized and unissued preferred stock as Series A Non-Voting Preferred Stock, or Series A Preferred Stock, and established the rights, preferences and privileges of the Series A Preferred Stock, which are summarized below.

Voting rights. Except as otherwise provided herein or as otherwise required by the DGCL, the Series A Preferred Stock shall have no voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock under the Certificate of Designation, (b) amend our certificate of incorporation or other organizational documents, including this Certificate of Designation, in any manner that adversely affects any rights of the holders in a way that is material and disproportionate to other shareholders of the Company, (c) increase the number of authorized shares of Series A Preferred Stock (other than as a result of a pro rata stock split or similar corporate action), or (d) enter into any agreement with respect to any of the foregoing, the effectiveness of which is not conditioned on obtaining such vote.

Dividends. Subject to a determination by the board of directors that a distribution is not prohibited pursuant to applicable provisions of the DGCL (including Section §170 thereof) or other applicable law (including any law requiring the affirmative vote of all or any portion of the company’s shareholders to effectuate any such dividend, in which event such dividend shall be conditioned upon obtaining such vote, but there will be no requirement for the Company to seek or solicit such shareholder votes), holders shall be entitled to receive from time to time and without interest, and the company shall pay, the holders, pro-rata, the net proceeds from the sale of certain assets held by the company.

Cancelation. Upon the payment of all dividends paid with respect to the sale of the assets, and subject to any limitations imposed by the DGCL, each share of Series A Preferred Stock shall, automatically and without any action on the part of the holder thereof, cease to be outstanding and shall be cancelled and returned to the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Preferred Stock, and any holder thereof shall thereafter cease to have any rights with respect to such shares.

Rights upon liquidation. In the event of a liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or a fundamental transaction (as defined in the Certificate of Designation), in each case occurring prior to the cancellation of the Series A Preferred Stock, then, in the case of a liquidation, after the payment or adequate provision for the payment of the Company’s liabilities and obligations, the holders shall be entitled to receive an amount equal to any accrued and unpaid dividends then owed under this Certificate of Designation provided however that in the event such amount would result in a net per share dividend of less than $0.01, such amount of will revert to the Company and no additional dividend payments will be paid.

7

Description of Depositary Shares

We may offer depositary shares, which will be evidenced by depositary receipts, representing fractional interests in shares of preferred stock of any series. In connection with the issuance of any depositary shares, we will enter into a deposit agreement with a bank or trust company, as depositary, which will be named in the applicable prospectus supplement. The following briefly summarizes the material provisions of the deposit agreement and of the depositary shares and depositary receipts, other than pricing and related terms disclosed for a particular issuance in an accompanying prospectus supplement. This description is not complete and is subject to, and qualified in its entirety by reference to, all provisions of the deposit agreement, depositary shares and depositary receipts. You should read the particular terms of any depositary shares and any depositary receipts that we offer and any deposit agreement relating to a particular series of preferred stock described in more detail in a prospectus supplement. The prospectus supplement will also state whether any of the generalized provisions summarized below do not apply to the depositary shares or depositary receipts being offered.

General

We may, at our option, elect to offer fractional shares of preferred stock, rather than full shares of preferred stock. In this event, we will issue receipts for depositary shares, each of which will represent a fraction of a share of a particular series of preferred stock. For a description of our preferred stock, see “Description of Capital Stock — Preferred Stock.”

The shares of any series of preferred stock represented by depositary shares will be deposited under a deposit agreement between us and the depositary we select. Each owner of a depositary share will be entitled to all the rights and preferences of the underlying preferred stock, including any dividend, voting, redemption, conversion and liquidation rights described in the particular prospectus supplement, in proportion to the applicable fraction of a share of preferred stock represented by such depositary share.

The depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of preferred stock in accordance with the terms of the applicable prospectus supplement.

Dividends and Other Distributions

The preferred stock depositary will distribute all cash dividends or other cash distributions, if any, received in respect of the deposited preferred stock to the record holders of depositary shares relating to the preferred stock in proportion to the number of depositary shares owned by such holders on the relevant record date.

In the case of a distribution other than in cash, the preferred stock depositary will distribute any property received by it other than cash to the record holders of depositary shares entitled to receive it in proportion to the number of depositary shares owned by such holder. If the preferred stock depositary determines that it is not feasible to make such a distribution, it may, with our approval, sell the property and distribute the net proceeds from the sale to the holders of the depositary shares.

The amounts distributed in any such distribution, whether in cash or otherwise, will be reduced by any amount required to be withheld by us or the preferred stock depositary on account of taxes.

Withdrawal of Preferred Stock

Unless otherwise indicated in the applicable prospectus supplement and unless the related depositary shares have been called for redemption, when a holder surrenders depositary receipts at the office of the preferred stock depositary maintained for that purpose, and pays any necessary taxes, charges or other fees, the holder will be entitled to receive the number of whole shares of the related series of preferred stock, and any money or other property, if any, represented by the holder’s depositary shares. Once a holder exchanges depositary shares for whole shares of preferred stock, that holder generally cannot “re-deposit” these shares of preferred stock with the preferred stock depositary, or exchange them for depositary shares. If a holder delivers depositary receipts that represent a number of depositary shares other than a whole number of shares of preferred stock for redemption or exchange, the preferred stock depositary will issue a new depositary receipt to the holder that evidences the remainder of depositary shares at the same time that the preferred stock is withdrawn.

8

Redemption, Conversion and Exchange of Preferred Stock

If a series of preferred stock represented by depositary shares is to be redeemed, the depositary shares will be redeemed from the proceeds received by the preferred stock depositary resulting from the redemption, in whole or in part, of that series of preferred stock. The depositary shares will be redeemed by the preferred stock depositary at a price per depositary share equal to the applicable fraction of the redemption price per share payable in respect of the shares of preferred stock redeemed.

Whenever we redeem shares of preferred stock held by the preferred stock depositary, the preferred stock depositary will redeem, as of the same date, the number of depositary shares representing shares of preferred stock redeemed. If fewer than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by the preferred stock depositary by lot or ratably or by any other equitable method, in each case as we may determine.

If a series of preferred stock represented by depositary shares is to be converted or exchanged, the holder of depositary receipts representing the shares of preferred stock being converted or exchanged will have the right or obligation to convert or exchange the depositary shares evidenced by the depositary receipts.

After the redemption, conversion or exchange date, the depositary shares called for redemption, conversion or exchange will no longer be outstanding. When the depositary shares are no longer outstanding, all rights of the holders will end, except the right to receive money, securities or other property payable upon redemption, conversion or exchange.

Voting Deposited Preferred Stock

Upon receipt of notice of any meeting at which the holders of any series of deposited preferred stock are entitled to vote, the preferred stock depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts evidencing the depositary shares relating to that series of preferred stock. Each record holder of the depositary receipts on the record date will be entitled to instruct the preferred stock depositary to vote the amount of the preferred stock represented by the holder’s depositary shares. The preferred stock depositary will try, if practical, to vote the amount of such series of preferred stock represented by such depositary shares in accordance with such instructions.

We will agree to take all reasonable actions that the preferred stock depositary determines are necessary to enable the preferred stock depositary to vote as instructed. The preferred stock depositary will abstain from voting shares of any series of preferred stock held by it for which it does not receive specific instructions from the holders of depositary shares representing those preferred shares.

Amendment and Termination of the Deposit Agreement

The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may at any time be amended by agreement between us and the preferred stock depositary. However, any amendment that materially and adversely alters any existing right of the holders of depositary receipts will not be effective unless the amendment has been approved by the holders of depositary receipts representing at least a majority of the depositary shares then outstanding. Additionally, in the case of amendments relating to or affecting rights to receive dividends or distributions or voting or redemption rights, approval is also required by the holders of depositary receipts representing not less than a specified percentage or all of the depositary shares of such series or class then outstanding, as provided in the applicable prospectus supplement. Every holder of an outstanding depositary receipt at the time any such amendment becomes effective will be deemed, by continuing to hold the depositary receipt, to consent and agree to the amendment and to be bound by the deposit agreement, as amended.

9

We may direct the preferred stock depositary to terminate the deposit agreement at any time by mailing notice of termination to the record holders of the depositary receipts then outstanding at least 30 days prior to the date fixed for termination. Upon termination, the preferred stock depositary will deliver to each holder of depositary receipts, upon surrender of those receipts, such number of whole shares of the series of preferred stock represented by the depositary shares together with cash in lieu of any fractional shares, to the extent we have deposited cash for payment in lieu of fractional shares with the preferred stock depositary. In addition, the deposit agreement will automatically terminate if:

all of the outstanding shares of the preferred stock deposited with the preferred stock depositary have been withdrawn, redeemed, converted or exchanged; or
there has been a final distribution in respect of the deposited preferred stock in connection with our liquidation, dissolution or winding up and the distribution has been made to the holders of the related depositary shares evidenced by depositary receipts.

Charges of Preferred Stock Depositary; Taxes and Other Governmental Charges

We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We also will pay charges of the preferred stock depositary in connection with the initial deposit of preferred stock and any redemption of preferred stock. Holders of depositary receipts will pay other transfer and other taxes and governmental charges and such other charges, including a fee for the withdrawal of shares of preferred stock upon surrender of depositary receipts, as are expressly provided in the deposit agreement to be for their accounts.

Prospective purchasers of depositary shares should be aware that special tax, accounting and other issues may be applicable to instruments such as depositary shares.

Resignation and Removal of Depositary

The preferred stock depositary may resign at any time by delivering to us notice of its intent to do so, and we may at any time remove the preferred stock depositary, any such resignation or removal to take effect upon the appointment of a successor preferred stock depositary meeting the requirements specified in the deposit agreement and its acceptance of such appointment.

Miscellaneous

The preferred stock depositary will forward all reports and communications from us which are delivered to the preferred stock depositary and which we are required to furnish to the holders of the deposited preferred stock.

Neither we nor the preferred stock depositary will be liable if we are or the preferred stock depositary is prevented or delayed by law or any circumstances beyond our or its control in performing our or its obligations under the deposit agreement. Our obligations and the obligations of the preferred stock depositary under the deposit agreement will be limited to performance in good faith of the duties under the deposit agreement, and we and the preferred stock depositary will not be obligated to prosecute or defend any legal proceeding in respect of any depositary shares, depositary receipts or shares of preferred stock unless satisfactory indemnity is furnished. We and the preferred stock depositary may rely upon written advice of counsel or accountants, or upon information provided by holders of depositary receipts or other persons believed to be competent and on documents believed to be genuine.

Description of Debt Securities

We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.

We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.

10

The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.

General

The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.

We may issue the debt securities issued under the indenture as “discount securities,” which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with “original issue discount,” or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.

We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:

the title of the series of debt securities;
any limit upon the aggregate principal amount that may be issued;
the maturity date or dates;
the form of the debt securities of the series;
the applicability of any guarantees;
whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination
if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;
the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;
our right, if any, to defer payment of interest and the maximum length of any such deferral period;

11

if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;
the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;
the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;
any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;
whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities;
the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities, and the depositary for such global security or securities;
if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders’ option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;
if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;
additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant;
additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;
additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;
the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;
whether interest will be payable in cash or additional debt securities at our or the holders’ option and the terms and conditions upon which the election may be made;
the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a “United States person” for federal tax purposes;
any restrictions on transfer, sale or assignment of the debt securities of the series; and
any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.

12

Conversion or Exchange Rights

We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.

Consolidation, Merger or Sale

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.

Events of Default under the Indenture

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue:

if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;
if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;
if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and
if specified events of bankruptcy, insolvency or reorganization occur.

If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.

The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.

13

Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:

the direction so given by the holder is not in conflict with any law or the applicable indenture; and
subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.

A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if:

the holder has given written notice to the trustee of a continuing event of default with respect to that series;
the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,
such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and
the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.

These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.

We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.

Modification of Indenture; Waiver

We and the trustee may change an indenture without the consent of any holders with respect to specific matters:

to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
to comply with the provisions described above under “Description Debt Securities–Consolidation, Merger or Sale;”
to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture;
to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;

14

to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;
to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under “Description of Debt Securities–General” to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;
to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.

In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:

extending the fixed maturity of any debt securities of any series;
reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or
reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.

Discharge

Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:

provide for payment;
register the transfer or exchange of debt securities of the series;
replace stolen, lost or mutilated debt securities of the series;
pay principal of and premium and interest on any debt securities of the series;
maintain paying agencies;
hold monies for payment in trust;
recover excess money held by the trustee;
compensate and indemnify the trustee; and
appoint any successor trustee.

In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.

15

Form, Exchange and Transfer

We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.

At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.

Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.

We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

If we elect to redeem the debt securities of any series, we will not be required to:

issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or
register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.

Information Concerning the Trustee

The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.

Payment and Paying Agents

Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

16

All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.

Governing Law

The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable.

Description of Rights

This section describes the general terms of the rights to purchase common stock or other securities that we may offer to stockholders using this prospectus. Further terms of the rights will be stated in the applicable prospectus supplement (or applicable free writing prospectus). The complete terms of the rights will be contained in the rights agreements we enter into with rights agents. These documents will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the rights agreements and any related documents. You also should read the prospectus supplement, which will contain additional information and which may update or change some of the information below. The following description and any description of the rights in a prospectus supplement (or applicable free writing prospectus) may not be complete and is subject to and qualified in its entirety by reference to the terms of any agreement relating to the rights.

Rights may be issued independently or together with any other security and may or may not be transferable. As part of any rights offering, we may enter into a standby underwriting or other arrangement under which the underwriters or any other person would purchase any securities that are not purchased in such rights offering. If we issue rights, each series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent, that will be named in the applicable prospectus supplement. Further terms of the rights will be stated in the applicable prospectus supplement. The rights agent will act solely as our agent and will not assume any obligation to any holders of rights certificates or beneficial owners of rights. The rights agreements and rights certificates will be filed with the SEC as an exhibit to the registration statement of which this prospectus is a part or as an exhibit to a filing incorporated by reference in the registration statement. See “Where You Can Find Additional Information” for information on how to obtain copies of the rights agreements and rights certificates.

The prospectus supplement relating to any rights we offer will describe the specific terms of the offering and the rights, including the record date for stockholders entitled to the rights distribution, the number of rights issued and the number of shares of common stock that may be purchased upon exercise of the rights, the exercise price of the rights, the date on which the rights will become effective and the date on which the rights will expire, and any applicable U.S. federal income tax considerations.

In general, a right entitles the holder to purchase for cash a specific number of shares of common stock or other securities at a specified exercise price. The rights are normally issued to stockholders as of a specific record date, may be exercised only for a limited period of time and become void following the expiration of such period. If we determine to issue rights, we will accompany this prospectus with a prospectus supplement that will describe, among other things:

the record date for stockholders entitled to receive the rights;
the number of shares of common stock or other securities that may be purchased upon exercise of each right;
the exercise price of the rights;
the terms for changes to or adjustments in the exercise price, if any;
whether the rights are transferable;

17

the period during which the rights may be exercised and when they will expire;
the steps required to exercise the rights;
whether the rights include “oversubscription rights” so that the holder may purchase more securities if other holders do not purchase their full allotments;
whether we intend to sell the shares of common stock or other securities that are not purchased in the rights offering to an underwriter or other purchaser under a contractual “standby” commitment or other arrangement;
our ability to withdraw or terminate the rights offering;
any material United States federal income tax consequences; and
other material terms, including terms relating to transferability, exchange, exercise or amendment of the rights.

If fewer than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby arrangements, as described in the applicable prospectus supplement. After the close of business on the expiration date, all unexercised rights will become void.

Description of Warrants

The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus.

General

We may issue warrants for the purchase of common stock, in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.

We plan to evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.

We will describe in the applicable prospectus supplement the terms of the series of warrants, including:

the offering price and aggregate number of warrants offered;
the currency for which the warrants may be purchased;
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;
if applicable, the date on and after which the warrants and the related securities will be separately transferable;

18

the number of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;
the terms of any rights to redeem or call the warrants;
any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;
the periods during which, and places at which, the warrants are exercisable;
the manner of exercise;
the dates on which the right to exercise the warrants will commence and expire;
the manner in which the warrant agreement and warrants may be modified;
if applicable, a discussion of certain material U.S. federal income tax considerations of holding or exercising the warrants; and
any other specific terms, preferences, rights or limitations of or restrictions on the warrants.

Description of Units

We may issue units comprised of one or more of the other securities described in this prospectus or in any prospectus supplement in any combination. Each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date or upon the occurrence of a specified event or occurrence.

The applicable prospectus supplement relating to units offered under this prospectus will describe the following terms, where applicable, of such units:

the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;
any unit agreement under which the units will be issued;
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and
 whether the units will be issued in fully registered or global form.

PLAN OF DISTRIBUTION

We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. A distribution of these securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:

at a fixed price or prices, which may be changed;
at market prices prevailing at the time of sale;

19

at prices related to such prevailing market prices; or
at negotiated prices.

We may also sell equity securities covered by this registration statement in an “at the market offering” as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:

on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or

to or through a market maker other than on the Nasdaq Global Market or such other securities exchanges or quotation or trading services.

Such at-the-market offerings, if any, may be conducted by underwriters acting as principal or agent.

A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:

the name or names of the underwriters, if any;
the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale;
any over-allotment options under which underwriters may purchase additional securities from us;
any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation;
any public offering price;
any discounts or concessions allowed or reallowed or paid to dealers; and
any securities exchange or market on which the securities may be listed.

Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement.

If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.

We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.

We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

20

We may provide agents and underwriters with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.

All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

Any underwriters or agents that are qualified market makers on the Nasdaq Global Market engage in passive market making transactions in the common stock on the Nasdaq Global Market accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

LEGAL MATTERS


The validity of the issuance of the securities offered hereby will be passed upon for us by the Silvestre Law Group, P.C., Westlake Village, California. The Silvestre Law Group, P.C. or its affiliates orand principals beneficially own 83,000approximately 150,000 shares of our Class A common stock.


EXPERTS


Our consolidated balance sheets as of December 31, 20162019 and 20152020 and the related consolidated statement of operations, stockholders' deficitstockholders’ equity and cash flows for the years ended December 31, 20162019 and 2015 included2020 incorporated by reference in this prospectus have been audited by RBSM LLP, independent registered public accounting firm, as indicated in their report with respect thereto, and have been so included in reliance upon the report of such firm given on their authority as experts in accounting and auditing.


WHERE YOU CAN FIND MORE INFORMATION

This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with information that is different from that contained in this prospectus nor in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus.

21

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including SRAX. The address of the SEC website is www.sec.gov. We maintain a website at www.srax.com. Information contained in or accessible through our website does not constitute a part of this prospectus.

INFORMATION INCORPORATED BY REFERENCE


The SEC permitsallows us to “incorporate by reference” the information contained in documents we file with the SEC,into this prospectus, which means that we can disclose important information to you by referring you to thoseanother document filed separately with the SEC. The SEC file number for the documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus, and you should read it with the same care that you read this prospectus. Later information that we file with the SEC will automatically update and supersede the information that is either contained, or001-37916. The documents incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed.

We incorporate by reference into this prospectus thecontain important information that you should read about us.

The following documents and information filed with the SEC:are incorporated by reference into this document:


·

Ourour Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 31, 2017, for the year ended December 31, 2016, and Annual Report on Form 10-K/A (Amendment No. 1) filed with the SEC on April 28, 2017 for the year ended December 31, 2016;

2021;

·

Ourour Quarterly Reports on Form 10-Q for the fiscal quarters ended March, 31, 2021, June 30, 2021 and September 30, 2017,2021, filed with the SEC on May 24, 2021, August 16, 2021 and November 15, 2021;

the information specifically incorporated by reference in our Annual Report on Form 10-K for the year ended December 31, 2020, from our definitive proxy statement relating to our 2021 annual meeting of stockholders, which was filed on May 15, August 14, and November 14, 2017, respectively;

April 30, 2021;

·

Our Definitive Proxy Statementsour Current Reports on Form 14A for our Special Meetings of Stockholders,8-K (other than information furnished, rather than filed) filed with the SEC on January 20, 20176, 2021, February 9, 2021, February 22, 2021, February 22, 2021, February 23, 2021, March 16, 2021, April 1, 2021, May 18, 2021, May 27, 2021, June 29, 2021, September 24, 2021, November 16, 2021, and May 22, 2017;

December 30, 2021; and

·

Our Current Reports on Forms 8-K filed with the SEC on January 4, 12, 20, 27, February 17, March 28, April 21, May 4, June 6, 27, September 13, 25, October 2, 27 and November 13, 24, 2017 (excluding any information furnished in such reports under Item 2.02, Item 7.01 or Item 9.01); and

·

The description of our Class A common stock and related rights contained in our registration statement on Form S-1 filed with the SEC on January 24, 2012, including any amendmentamendments or reportreports filed for the purpose of updating such description;description.

All filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus.

 

We also incorporate by reference into this prospectus all additional documentsany future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that we fileare related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC under the terms of Sectionpursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act, of 1934 that areincluding those made after the date of the initial filing of the registration statement of which this prospectus is a part and beforeprior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities offeredmade by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. We are not, however, incorporating,Any statements in each case, any documents or information that we aresuch future filings will automatically be deemed to furnishmodify and not filesupersede any information in accordanceany document we previously filed with the SEC rules.that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.

 

You mayWe will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus at no cost,but not delivered with the prospectus, including exhibits which are specifically incorporated by writing or telephoning us at the following address: Corporate Secretary, Social Reality, Inc., 456 Seaton Street, Los Angeles, CA 90013, telephone number (323) 694-9800.

















[srax_s3003.jpg]


SOCIAL REALITY, INC.reference into such documents. You should direct any requests for documents to:

 

4,746,820 Class A Shares of Common StockSRAX, Inc.
2629 Townsgate Rd., Suite 215

Westlake Village, CA 91361
323-694-9800
Attention: Chief Financial Officer

 

22

Srax_logo_highres

SRAX, INC.

 

$100,000,000

CLASS A COMMON STOCK

PREFERRED STOCK

DEPOSITORY SHARES

DEBT SECURITIES

RIGHTS

PURCHASE CONTRACTS

WARRANTS

UNITS

 

PROSPECTUS

 

, 20172021

 

 








PART II


II. INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14.Other Expenses of Issuance and Distribution.


Item 14.

Other Expenses of Issuance and Distribution.


The aggregate estimated (other than the registration fee) expenses payable by the Company in connection with a distribution of securities registered hereby are as follows:

 

SEC registration and filing fee

 

$

3,410.27

 

Accounting fees and expenses

 

 

10,000.00

 

Legal fees and expenses

 

 

5,000.00

 

Printing and engraving expenses

 

 

1,000.00

 

Transfer Agent fees and Expenses

 

 

1,000.00

 

Miscellaneous

 

 

1,000.00

 

TOTAL

 

$

21,410.27

 

Securities and Exchange Commission Registration Fee $9,270 
Legal Fees and Expenses $50,000 
Accountants’ Fees and Expenses $40,000 
Miscellaneous $10,000 
Total $109,270 


All fees and expenses other than the SEC registration and filing fee are estimated.

Item 15.Indemnification of Directors and Officers.


Item 15.

Indemnification of Directors and Officers.


Our amended and restated certificate of incorporation as amended, contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal liability of directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. Our amended and restated certificate of incorporation as amended, and bylaws provide that we shall indemnify our directors and executive officers and may indemnify our employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.

 

Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of the corporation against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.


We have also entered into indemnification agreements with certain of our directors and executive officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to Social Reality, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.


We have also purchased and intend to maintain insurance on behalf of any person who is or was a director or officer of our company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

 

We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the registrant’s amended and restated certificate of incorporation and amended and restated bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Company regarding which indemnification is sought. The indemnification provisions in our amended and restated certificate of incorporation, amended and restated bylaws and the indemnification agreements entered into or to be entered into between the registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the registrant’s directors and executive officers for liabilities arising under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of ours pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

The registrant currently carries liability insurance for its directors and officers.

See also the undertakings set out in our response to Item 17 herein.

II-1


Item 16.

Exhibits.


A list of exhibits filed herewith is contained in the exhibit index that immediately precedes such exhibits and is incorporated herein by reference.




II-1




Item 17.

Undertakings.


Item 16.

(a)

The undersigned registrant hereby undertakes:

Exhibits.

 

Exhibit
Number
Description of Document

4.1*

(1)

To file, during any periodForm of warrant agreement and warrant certificate

4.2*Form of specimen preferred stock certificate
4.3*Certificate of designation for preferred stock
4.4Form of debt indenture
4.5*Form of Indenture Security
4.6*Form of rights agreement
4.7*Form of Deposit Agreement
5.1+Opinion of Silvestre Law Group, P.C.
23.1Consent of Independent Registered Public Accounting Firm
23.2+Consent of Silvestre Law Group, P.C. (Included in which offers or sales are being made, a post-effective amendmentExhibit 5.1)
24.1Powers of Attorney (included on signature page to this registration statement:

statement)
25.1**Form T-1 Statement of Eligibility of the Trustee under the Debt Indenture

* To the extent applicable, to be filed by a post-effective amendment or as an exhibit to a document filed under the Exchange Act and incorporated by reference herein.

** To be subsequently filed, when appropriate, pursuant to Section 305(b)(2) of the Trust Indenture Act of 1939, as amended.

+ To be filed by amendment.

Item 17. Undertakings.

 

a.

(i)

To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

The undersigned Registrant hereby undertakes:

 

1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(ii)

To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

 

(iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

i. To include any prospectus required by Section 10(a)(3) of the Securities Act;

ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

iii. To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the registration statement;

Provided however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrantRegistrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

 

(2)2. That, for the purpose of determining any liability under the Securities Act, of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-2

(3)

3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4)4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

(i)(A)i. Each prospectus filed by the registrantRegistrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(B)ii. Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Sectionsection 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initialbona fide offering thereof.thereof; Provided,provided, however, that no statement made in a registration statement or prospectus that is part of the registration statementRegistration Statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statementRegistration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; ordate.

 



5. That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

II-2



 


i. Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

(5)

ii. Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

iii. The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

iv. Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

b. The undersigned registrantRegistrant hereby undertakes that, for purposes of determining any liability under the Securities Act, of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statementRegistration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(6)h. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrantRegistrant pursuant to the foregoing provisions, or otherwise, the registrantRegistrant has been advised that in the opinion of the Securities and Exchange CommissionSEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrantRegistrant of expenses incurred or paid by a director, officer or controlling person of the registrantRegistrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrantRegistrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




j. If and when applicable, the undersigned Registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Act.


II-3




II-3



 


SIGNATURES

SIGNATURES


Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Los Angeles,Westlake Village, California on December 8, 2017.30, 2021.


SRAX, Inc.

Social Reality, Inc.

By:

By:

/s/ Christopher Miglino

Christopher Miglino

Chief Executive Officer


SIGNATURES AND POWER OF ATTORNEY

 

We, the undersigned officers and directors of Social Reality,SRAX, Inc., hereby severally constitute and appoint Christopher Miglino as our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

 

SignatureTitleDate

Signature

Title

Date

/s/ Christopher Miglino

Chief Executive Officer, Director, President

December 8, 2017

30, 2021

Christopher Miglino

(principal executive officer)

/s/ Joseph P. HannanMichael Malone

Chief Financial Officer

December 8, 2017

30, 2021

Joseph P. Hannan

Michael Malone

(principal financial and accounting officer)

/s/ Kristoffer NelsonChristopher Lahiji

Chief Operating Officer, Director

December 8, 2017

30, 2021

Kristoffer Nelson

Christopher Lahiji

/s/ Marc Savas

Director

December 8, 2017

30, 2021

Marc Savas

/s/ Malcolm CasSelleBrock Pierce

Director

December 8, 2017

30, 2021

Malcolm CasSelle

Brock Pierce

/s/ Robert Jordan

Director

December 8, 2017

30, 2021

Robert Jordan

/s/ Coleen DeClaudioColleen DiClaudio

Director

December 8, 2017

30, 2021

ColeenColleen DiClaudio

II-4

 

/s/ Matthew Weiss

Director

December 8, 2017

Matthew Weiss



II-4




INDEX TO EXHIBITS



 

 

 

 

 

 

Incorporated by Reference

Exhibit

No.

 


Description

 

Filed

Herewith

 

Form

 

Exhibit

No.

 

File No.

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

 

 

3.01(i)

 

Certificate of Incorporation filed on 8/2/2011

 

 

 

S-1

 

3.01(i)

 

333-179151

 

1/24/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.02(i)

 

Certificate of Correction of Certificate of Incorporation filed on August 30, 2011

 

 

 

S-1

 

3.01(ii)

 

333-179151

 

1/24/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.03(i)

 

Certificate of Amendment to the Certificate of Incorporation of Social Reality, Inc. filed on 9/6/2016

 

 

 

8-K

 

3.5

 

000-54996

 

9/19/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

3.04(ii)

 

Bylaws of Social Reality, Inc.

 

 

 

S-1

 

3.03

 

333-179151

 

1/24/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

4.01

 

Form of Series A-1 and A-2 12.5% Senior Secured Convertible Debenture issued October 27, 2017

 

 

 

8-K

 

4.01

 

001-37916

 

10/27/17

 

 

 

 

 

 

 

 

 

 

 

 

 

4.02

 

Form of Series A Warrant Issued October 27, 2017

 

 

 

8-K

 

4.02

 

001-37916

 

10/27/17

 

 

 

 

 

 

 

 

 

 

 

 

 

4.03

 

Form of Placement Agent Warrant issued on October 27, 2017

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5.01

 

Opinion of Silvestre Law Group, P.C.

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of RBSM LLP

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.2

 

Consent of Silvestre Law Group, P.C. (included in Exhibit 5.01)

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (see page II-4)

 

*